News Medical on MSN10h
MHRA greenlights donanemab for early stage Alzheimer’s disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab can slow the progression of Alzheimer’s disease.But what is the drug and how does it work? Here your questions on ...
STAT3d
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...
Tens of thousands to be recruited into Alzheimer’s trials after landmark drug rejected
Tens of thousands of people will be recruited into Alzheimer’s trials after a landmark drug was rejected for use on the NHS.
Alzheimer's Society3d
Alzheimer's Society responds to MHRA and NICE announcements on donanemab
The MHRA have approved donanemab for the treatment of Alzheimer’s disease. However, NICE does not recommend use on the NHS ...
Outsourcing-pharma3d
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
National Institute for Health and Care Excellence3d
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...
Second ‘game-changing’ Alzheimer’s drug donanemab gets green light in UK – but WON’T be available on NHS
A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
The Pharma Letter3d
Second Alzheimer’s drug, donanemab, rejected for NHS use
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...
Arkansas group suggests ways to improve care for Alzheimer’s, dementia patients
Expanding public education, increasing access and quality of care, supporting family caregivers and increasing training for ...